Clinicopathological study of basal cell carcinoma over a period of nine years from Uttar Pradesh

Shweta Grover¹*, Rani Bansal²

¹Associate Professor, ²Professor, Dept. of Pathology, Subharti Medical College, Meerut, Uttar Pradesh, India

DOI: 10.18231/2394-6792.2018.0039

Abstract

Introduction: Basal cell carcinoma is the most common type of skin cancer and occurs mostly in the head and neck region in middle age to elderly people. It has varied clinical presentation and also many morphologic/histopathologic subtypes.

Aim of the Study: To study the spectrum of basal cell carcinomas in our institute over a nine year period.

Materials and Methods: This was a prospective study carried out at Subharti Medical College, Meerut, Uttar Pradesh, over a period of nine years. All the basal cell carcinomas reported during this period were studied for clinical presentation, demographic details, anatomical location of tumor, macroscopic and microscopic appearance.

Results: A total of 28 cases of BCC were reported. The patient age ranged from 14 to 85 years and the male to female ratio was 2.1:1. Most of the cases occurred over 40 years and all the tumors occurred in the facial region. Clinically, ulcerative and nodular presentation was more common. One case of nevoid BCC syndrome was also seen.

Conclusion: Basal cell carcinoma commonly occurs in the face region and its incidence increases with advancing age. It has varied clinical presentations and histologic subtypes. Early diagnosis gives better prognosis. Basal cell carcinoma in a young person or child should be evaluated for nevoid BCC syndrome.

Keywords: Basal cell carcinoma, Histologic subtypes of BCC, Nevoid BCC syndrome.

Introduction

Basal cell carcinoma (BCC) is considered as the most common type of skin cancer (75% to 80%). Almost 80% of BCC occur in the head and neck region, followed by the trunk (about 25%), and very rarely at uncommon sites such as penis, vulva, or perianal skin (about 5%). Light-skinned and fair people are more susceptible to BCC. The population residing in equatorial areas and high altitude areas are more prone to BCC. In general, Asians and dark skinned people show low incidence for BCC.¹ Various risk factors are suspected in the causation of BCC like exposure to arsenic,² tar, coal, paraffin,³ some industrial oils, radiation, burn scars⁴ xeroderma pigmentosa⁵ previous trauma,⁶ and immune suppression.⁷ By and large chronic ultraviolet radiation exposure is considered as the most important risk factor for basal cell carcinoma.⁸

Many times a shave biopsy is sufficient for the diagnosis of BCC. A punch biopsy from the lesion can also be studied especially if the shave biopsy results are negative inspite of a strong clinical suspicion of BCC.

Materials and Methods

This was a prospective study carried out in the department of Pathology, Subharti Medical College, Meerut, Uttar Pradesh, over a period of nine years from January 2008 to October 2017.

All the basal cell carcinomas (n=28) reported during this period were studied for clinical presentation, demographic details, anatomical site of tumor, macroscopic and microscopic appearance.

The specimens were received from the departments of Dermatology, Ophthalmology and General Surgery and were a mix of mostly excision biopsy specimens and a few punch biopsy specimens. The tissue was fixed in 10% buffered neutral formalin and was taken for routine histopathological processing. The sections were cut at five micron thickness, were stained with hematoxylin and eosin and were examined for light microscopy. Immunohistochemistry was used in a few cases.

Observations and Results

The patient age ranged from 14 years to 85 years. There were 19 males and 9 females and the male to female ratio was 2.1:1.

| Table 1 Age and gender wise distribution of the cases (n=28) |
|---|---|---|---|
| Age (in years) | Total cases (%) | Males | Females |
| | No. of cases | Percentage (%) | No. of cases | Percentage (%) |
| 11-20 | 1 (3.5%) | 1 | 5.2% | 0 | 0 |

*Corresponding Author: Email: drshwetagrover@gmail.com

Received: 4th December, 2017 Accepted: 1st January, 2018

Accepted: 08th February, 2018
Males were affected more commonly and the most number of cases of BCC were seen above 40 years.

**Laterality of the lesions:** The left and right side of the body were affected in 11 (39.2%) and 16 (57.1%) cases respectively. Only one case (2.8%) showed midline lesion.

| Site                  | No. of cases | Percentage (%) |
|-----------------------|--------------|----------------|
| Forehead              | 3            | 10.7%          |
| Cheek                 | 7            | 25.0%          |
| Upper eyelid          | 5            | 17.8%          |
| Lower eyelid          | 5            | 17.8%          |
| Nose                  | 3            | 10.7%          |
| Ala of nose           | 1            | 3.5%           |
| Lip                   | 1            | 3.5%           |
| Posterior auricular region | 3   | 10.7%          |
| Total                 | 28           | 100%           |

One case of Nevoid BCC syndrome was seen in a 66 year old male patient who had multiple BCCs on the back and face region (right lower eyelid)

**Gross morphology of basal cell carcinoma:** Out of 28 cases, Ulcer was seen in 15 (53.5%) cases. Nodular lesion was seen in 10 (35.7%) cases and as Fungating mass was seen in 3 (10.7%) cases.

**Histopathological type of basal cell carcinoma**

| Histopathology          | No. of cases | Percentage (%) |
|-------------------------|--------------|----------------|
| Conventional            | 16           | 57.1%          |
| Nodulo-cystic type      | 4            | 14.2%          |
| Adenoid cystic type     | 3            | 10.7%          |
| Squamous differentiation | 3            | 10.7%          |
| Nevoid BCC type         | 1            | 3.5%           |
| Pigmented type          | 1            | 3.5%           |
| Total                   | 28           | 100%           |

The conventional type was most common on histopathological examination accounting for 16 (57.1%) cases.

**Discussion**

In the present study 28 cases of Basal cell carcinoma were studied.
canthus (5%). In our study the upper and lower eyelid areas were affected in equal number of cases.\textsuperscript{18}

**Macroscopic appearance:** Many clinical variants have been reported in the literature such as the nodular variant, ulcerated type, pigmented type, fibroepithelioma of pinkus, superficial spreading type, cystic type, infiltrated type, morpheaform type etc.\textsuperscript{19} In our study, the most common clinical presentation was that of a non-healing ulcer on the face seen in 15 (53.5\%) cases.

Also recently described is the “Red dot basal cell carcinoma” which is a unique variant of basal cell carcinoma. Very few cases have been reported of this variant and all the patients were above seventy years. BCCs do not blanch on diascopy but this particular variant may show blanching and cause delay in the diagnosis.\textsuperscript{20}

**Microscopic appearance:** Many microscopic types have been reported in the literature such as the superficial type, basosquamous/metatypical type, granular BCC, clear cell BCC, infundibulocystic BCC, fibroepithelial tumor of Pinkus and sarcomatoid BCC,\textsuperscript{21} pigmented type, cystic type and morpheaform type BCC.\textsuperscript{19} In the present study 53.5\% cases showed the conventional or routine histologic appearance for BCC. The variant histologic subtypes were rare. Squamous differentiation i.e keratotic areas in BCC were encountered in 3 (10.7\%) cases. This has to be differentiated from the basosquamous/metatypical BCC where the squamous elements show atypical features and confer a more aggressive behavior and metastatic potential to these tumors.\textsuperscript{22}

The Microscopic appearance of Nevoid BCC is histologically similar to sporadic BCC. A histologic clue that is suggestive of Nevoid BCC is the finding of multiple minute buds of early superficial BCC in normal adjacent skin of excision tissue of BCC. Also admixture of different histologic patterns of BCC is common in Nevoid BCC.\textsuperscript{23}

**Nevoid basal cell carcinoma syndrome:** Also known as Gorlin syndrome is characterized by multiple BCCs, palmar pits, keratocysts of the jaw, central nervous system abnormalities with dural calcifications, skeletal anomalies and endocrine defects.\textsuperscript{21} Rahbari et al\textsuperscript{10} observed in their study that 2\% of patients less than 45 years of age with basal cell carcinomas have this syndrome. In our study, there was a single patient (3.5\%) who was diagnosed on histopathology as Nevoid BCC. On further evaluation he was found to have some of the symptoms associated with Gorlin’s syndrome. He also gave a positive family of an elder brother having similar symptoms and also an eighteen year old son with features suggestive of Gorlin’s syndrome who was under evaluation for the same. The patched/hedgehog intracellular signaling pathway is implicated in both sporadic BCCs and nevoid BCC syndrome (Gorlin syndrome). Mutations in the PTCH 1 (PATCHED) (patched) gene on chromosome 9q22.3 are of particular interest in causation of BCC.

Genetic testing was advised for our patient and also for his family members if possible but could not be done due to cost constraints. However, immunohistochemistry was performed for this patient of Nevoid BCC considering trichoepithelioma as a close histologic differential. The distinction between the two entities is very important as BCC is a malignant tumor and trichoepithelioma is a benign lesion. Immunohistochemistry was done for Bcl2, CD10 and CD34. In BCC, immunostaining for bcl-2 is diffuse whereas, it is peripheral in trichoepithelioma. CD34 is more positive in the stroma of trichoepithelioma than BCC and absent in tumor cells of both tumors. In BCC, CD10 stains the epithelial tumor cells, whereas, in trichoepithelioma CD10 stains the stromal cells.\textsuperscript{24} Our IHC results favoured a diagnosis of BCC.

**Clinical behavior:** The prognosis of BCC is excellent, with a 100\% survival rate for cases that have not spread to other sites. Basal cell carcinomas are slow to develop and very rarely metastasize. The incidence of metastasis in BCC ranges from 0.0028\% to 0.55\%.\textsuperscript{25} Inspite of low metastatic potential it is very important to have an early diagnosis because most of these tumors; almost 75\%; occur on the face, and head and neck region. BCCs are locally invasive and can cause significant cosmetic disfigurement in these areas, destruction of vital structures and also are not amenable to extensive surgical resections in face region.\textsuperscript{26} A few of our cases were followed up for some time. None of them had any metastasis. Most of the cases were lost to follow up. Snow et al\textsuperscript{27} used the data at Moh’s Surgery Clinic and observed that BCCs more than 3 cm in diameter had a metastatic incidence of 1.9\% and also that larger lesions of stage T3 or T4 should be followed up for a minimum of ten years for delayed metastasis. The most common sites of metastasis are the lymph nodes and lungs.\textsuperscript{28} Various treatment modalities are available for BCC and treatment is curative in about 95\% of cases. Despite treatment, recurrences are known to occur especially in the first year, or it may develop in new sites. So for this very reason, regular dermatological screenings are recommended.\textsuperscript{29}

**Treatment Modalities:** Many treatment modalities are available for BCC but surgery is considered the “gold standard” for the treatment of vast majority of BCC. Surgical excision provides tissue specimen for complete histological analysis; gives a lower recurrence rate and also bestows a better cosmetic result. Mohs surgery is the treatment of choice for larger or recurrent and high risk lesions. Curettage and cautery are preferred for smaller BCCs. Radiotherapy is preferred in the elderl and for BCCs located on the head. Cryotherapy is used for very small lesions but gives a poor cosmetic result. Laser treatment is still under research. For smaller superficial lesions topical imiquimod, 5-fluorouracil and photodynamic therapy (PDT) can be used.\textsuperscript{9} The
choice of treatment depends on the age of the patient, exact location and size of the tumor, presence of invasion, risk of recurrence etc. Inspite of adequate treatment long term follow is strongly advisable.

Conclusion

Basal cell carcinoma commonly occurs in the face region, its incidence increases with advancing age and it has a male preponderance. It has varied clinical presentations and histologic subtypes. Early diagnosis gives better prognosis. Multiple basal cell carcinomas in an individual should prompt further evaluation for nevoid BCC syndrome.

References

1. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327:794-8.
2. Karagas MR, Gossai A, Pierce B, Ahsan H. Drinking Water Arsenic Contamination, Skin Lesions, and Malignancies: A Systematic Review of the Global Evidence.Curr Environ Health Rep. 2011;2(1):52-68.
3. Romao-Correa RF, Maria DA, Soma M, et al. Nucleolar organizer region staining patterns in paraffin-embedded tissue cells from human skin cancers. J Cutan Pathol. 2005;32(5):323-28.
4. Ozyazgan I, Kontas O. Previous injuries or scars as risk factors for the development of basal cell carcinoma. Scand J Plast Reconstr Surg Hand Surg. 2004. 38(1):11-5.
5. Mohanty P, Mohanty L, Devi BP. Multiple cutaneous malignancies in xeroderma pigmentosum. Indian J Dermatol Venereol Leprol. 2001;67(2):96-7.
6. Keyhani K, Ashenhurst M, Oryshak A. Periocular basal cell carcinoma arising in a site of previous trauma. Can J Ophthalmol. 2007;42(3):467-8.
7. Berking C, Hauschild A, Köhl R, Mast G, Gutzmer R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014;111:389-395.
8. Dessimioti C, Antoniou C, Katsambas A, Stratigos AJ. Basal cell carcinoma: What's new under the sun. Photochem Photobiol 2010;86:481-91.
9. Rezakovic S, Zuzul K, Kostovic K. Basal Cell Carcinoma – Review of Treatment Modalities. J Dermatolog Clin Res 2014; 2(5):1035.
10. Rahbabi H, Mehregan AH. Basal cell epithelioma (carcinoma) in children and teenagers. Cancer. 1982;49:350–353.
11. Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746-50.
12. Erba P, Farhadi J, Wettstein R, Arnold A, Harr T, Prier G. Morphoeic basal cell carcinoma of the face. Scand J Plast Reconstr Surg Hand Surg. 2007. 41(4):184-8.
13. Shindel AW, Mann MW, Lev KY, et al. Mohs micorgraphic surgery for penile cancer: management and long-term followup. J Urol. 2007 Nov. 178(5):1980-5.
14. Kara M, Colgecen E, Yildirim EN. Vulvar basal cell carcinoma. Indian J Pathol Microbiol. 2012;55 (4):583-4.
15. Philip R Cohen. Basal Cell Carcinoma of the Axilla: Review of the World Literature. American Journal of Clinical Dermatology 2014;15(2):95-100.
16. Newman JC, Leffell DJ. Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg. 2007;33(8):957-64.
17. Baxter JM, Patel AN, Varma S. Facial basal cell carcinoma. BMJ 2012;345: e5342.
18. Tse TG, Gilberg SM (1997) Malignant eyelid tumours. In: Krachmer JH, Mannis MJ, Holland EJ (eds) Cornea, vol II. Mosby, St. Louis, pp 601–605.
19. Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatol Online J. 2013.
20. Cohen PR. Red Dot Basal Cell Carcinoma: Report of Cases and Review of This Unique Presentation of Basal Cell Carcinoma. Cureus 2017;9(3): e1110. doi:10.7759/cureus.1110.
21. Rosai J 2011. Skin, Dermatoses, Tumors and Tumor like conditions. In: Rosai and Ackerman’s Surgical Pathology 10th edition, Volume I. Mosby, St. Louis, pp 135.
22. De Faria LJ, Navarrete MA. The histopathology of the skin basal cell carcinoma with areas of intermediate differentiation. A metatypical carcinoma? Pathol Res Pract 1991;187:978-985.
23. Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Head and Neck Pathol 2016;10(2):119-24.
24. Raheem, SA, Alshaar R., Tealeb A, Rushdy E. The Role of Bcl-2, CD10 and CD34 Expression in Differentiation between Basal Cell Carcinoma and Trichoepithelioma. Open Journal of Pathology 2014;4:116-124.
25. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014; 50: 774783.
26. Smith V, Walton S. Treatment of facial Basal cell carcinoma: a review. J Skin Cancer. 2011;2011:371-380.
27. Snow SN, Sahl W, Lo JS, Feyzi J. Metastatic basal cell carcinoma, Report of five cases. Cancer 1994; 73:328–35.
28. Patel MS, Thigpen JT, Vance RB, Elkins SL, Guo M. Basal cell carcinoma with lung metastasis diagnosed by fine-needle aspiration biopsy. South Med J. 1999; 92(3):321-4.
29. Mc Loone NM, Tolland J, Walsh M, et al. Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol. 2006;20(6):698-701.